• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Ionis Pharmaceuticals, Inc. - Common Stock (NQ:IONS)

    73.49 -0.99 (-1.33%)
    Streaming Delayed Price Updated: 9:41 AM EDT, Jun 8, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Ionis Pharmaceuticals, Inc. - Common Stock

    < Previous 1 2 3 Next >
    News headline image
    Ionis announces appointment of Ludwig Hantson, Ph.D. to Board of Directors
    From Ionis Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Ionis to present new analyses from CORE and CORE2 pivotal studies supporting olezarsen for severe hypertriglyceridemia (sHTG) at upcoming congresses
    From Ionis Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Ionis partner GSK announces bepirovirsen achieves unprecedented functional cure rates with potential to redefine treatment for chronic hepatitis B
    From Ionis Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Ionis partner Biogen announces topline results from Phase 2 CELIA study of diranersen (BIIB080): first study to show reduction in tau pathology and cognitive benefit in patients with early Alzheimer’s disease
    From Ionis Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Ionis to host 2026 virtual Annual Meeting of Stockholders
    From Ionis Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Ionis to present at upcoming investor conferences
    From Ionis Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Ionis reports first quarter 2026 financial results and highlights progress on key programs
    From Ionis Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Ionis partner GSK announces bepirovirsen accepted for Priority Review and granted Breakthrough Therapy Designation by U.S. FDA as a potential first-in-class medicine for chronic hepatitis B
    From Ionis Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Ionis presents new data from pivotal study of zilganersen in Alexander disease (AxD) at AAN 2026 Annual Meeting
    From Ionis Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Ionis to hold first quarter 2026 financial results webcast
    From Ionis Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Ionis announces zilganersen New Drug Application for Alexander disease (AxD) accepted by FDA for Priority Review
    From Ionis Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Ionis announces changes to Board of Directors
    From Ionis Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Ionis to present new data supporting DAWNZERA™ (donidalorsen) in hereditary angioedema at 2026 AAAAI Annual Meeting
    From Ionis Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Olezarsen sNDA accepted by the FDA for Priority Review for the treatment of severe hypertriglyceridemia (sHTG)
    From Ionis Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Ionis reports fourth quarter and full year 2025 financial results and highlights progress on key programs
    From Ionis Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Ionis to present at upcoming investor conferences
    From Ionis Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Ionis updates time for fourth quarter and full year 2025 financial results webcast
    From Ionis Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Ionis to hold fourth quarter and full year 2025 financial results webcast
    From Ionis Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Nature Medicine Publishes Results from the Pivotal DEVOTE Study of High-Dose Regimen of Nusinersen in Spinal Muscular Atrophy
    From Biogen Inc.
    Via GlobeNewswire
    News headline image
    DAWNZERA™ (donidalorsen) approved in the European Union for hereditary angioedema (HAE)
    From Ionis Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Biogen Receives European Commission Approval for High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy
    From Biogen Inc.
    Via GlobeNewswire
    News headline image
    Ionis well-positioned for continued momentum and substantial value creation in 2026 with two new independent launches and several pivotal data readouts
    From Ionis Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Ionis partner GSK announces positive topline results from B-Well 1 and B-Well 2 Phase 3 studies for bepirovirsen, a potential first-in-class medicine for chronic hepatitis B
    From Ionis Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Ionis to present at 44th Annual J.P. Morgan Healthcare Conference
    From Ionis Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Ionis receives U.S. FDA Breakthrough Therapy designation for zilganersen for Alexander disease (AxD)
    From Ionis Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Ionis receives U.S. FDA Breakthrough Therapy designation for olezarsen for severe hypertriglyceridemia (sHTG)
    From Ionis Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    High Dose Regimen of Nusinersen Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy
    From Biogen Inc.
    Via GlobeNewswire
    News headline image
    Biogen Completes Acquisition of Alcyone Therapeutics
    From Biogen Inc.
    Via GlobeNewswire
    News headline image
    DAWNZERA™ (donidalorsen) receives positive opinion from CHMP, recommended for approval in EU for hereditary angioedema (HAE)
    From Ionis Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Ionis Prices Convertible Notes Offering to Refinance 2026 Convertible Notes
    From Ionis Pharmaceuticals, Inc.
    Via Business Wire
    < Previous 1 2 3 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.